SCHEMBL19088566

SCHEMBL19088566

CN(C(=O)OC(C)(C)C)[C@@H](CC(C)(C)F)C(=O)O[C@H](Cc1ccc(C2=CCOCC2)cc1)C(=O)O

nearest known ligand 0.36

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 1/20 0.34
PPARG P37231 4/20 0.33
PPARA Q07869 4/20 0.33
CTSC P53634 1/20 0.32
ADORA1 P30542 1/20 0.32
GPBAR1 Q8TDU6 1/20 0.31
PTGER4 P35408 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18248177 0.91 ITGB3 (0.34) AAK1
SCHEMBL23279554 0.91 ITGB3 (0.34) AAK1
SCHEMBL18256349 0.91 ITGB3 (0.34) AAK1
SCHEMBL22502772 0.89 AAK1 (0.35) AAK1PPARGPPARACTSCADORA1
SCHEMBL19239217 0.87 AAK1 (0.30) AAK1
SCHEMBL19244985 0.85 BRD4 (0.33) AAK1
SCHEMBL19088502 0.83 CTSL (0.32) AAK1
SCHEMBL26034329 0.83 CTSL (0.32) AAK1
SCHEMBL21266632 0.83 ITGB3 (0.35) ADORA1
SCHEMBL18248022 0.82 L3MBTL1 (0.37) ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018048-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2024-06-25 US disclosed
EP-3397638-B1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) 2023-08-23 EP disclosed
US-20220098241-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS Boehringer Ingelheim Animal Health USA Inc. (US) 2022-03-31 US disclosed
US-11230571-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2022-01-25 US disclosed
US-10793604-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2020-10-06 US disclosed
US-20190248840-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS Boehringer Ingelheim Animal Health USA Inc. (US) 2019-08-15 US disclosed
US-10344056-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2019-07-09 US disclosed
US-20170233438-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS MERIAL INC. (US) 2017-08-17 US disclosed
US-20170233438-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS MERIAL INC. (US) 2017-08-17 US disclosed
WO-2017116702-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS MERIAL, INC. (US) 2017-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10344056-B2 Anthelmintic depsipeptide compounds VIP, PREP, DNPEP AAK1 3436/4885PPARG 3670/4885PPARA 3876/4885
US-12018048-B2 Anthelmintic depsipeptide compounds VIP, DNPEP, DPEP1 AAK1 3150/4885PPARG 3029/4885PPARA 3307/4885
US-20170233438-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS VIP, PREP, DNPEP AAK1 3436/4885PPARG 3670/4885PPARA 3876/4885
US-10793604-B2 Anthelmintic depsipeptide compounds VIP, PREP, DNPEP AAK1 3412/4885PPARG 3698/4885PPARA 3734/4885
US-20220098241-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS VIP, PREP, DNPEP AAK1 3436/4885PPARG 3670/4885PPARA 3876/4885
US-20190248840-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS VIP, PREP, DNPEP AAK1 3436/4885PPARG 3670/4885PPARA 3876/4885
US-11230571-B2 Anthelmintic depsipeptide compounds VIP, PREP, DNPEP AAK1 3436/4885PPARG 3670/4885PPARA 3876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.